Assessment of the Potential Interactions Between Cocaine and GBR 12909 - 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: January 17, 2003
Last updated: April 25, 2012
Last verified: March 2005
The purpose of this study is to assess the potential interactions between iv cocaine and GBR 12909.
Drug: GBR 12909
Primary Purpose: Treatment
||Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers
Primary Outcome Measures:
- Pharmacokinetic parameter comparison
| Estimated Enrollment:
| Study Start Date:
This is a single dose with escalation, double-blind, placebo-controlled inpatient study in which 24 cocaine experienced volunteers that meet protocol eligibility criteria during a 30 day screen period will be randomized into three dose groups.
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Must understand study procedures and provide written informed consent
- For additional inclusion criteria information, please contact study site for more information.
- Please contact study site for more information.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00051896
|Uniformed Services University of Health Science
|Bethesda, Maryland, United States, 20814 4799 |
||Louis Cantilena, M.D.
||Uniformed Services University of Health Science
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 17, 2003
||April 25, 2012
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 22, 2014
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs